Development and Validation of a Robust Multigene Signature as an Aid to Predict Early Relapse in Stage I-Iii Clear Cell and Papillary Renal Cell Cancer

Journal of Cancer - Australia
doi 10.7150/jca.38274
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

Early-Stage Clear Cell Tubulopapillary Renal Cell Carcinoma: Imaging Features and Distinction From Clear Cell and Papillary Subtypes

Abdominal Radiology
Nuclear MedicineRadiologyUrologyUltrasound TechnologyGastroenterologyRadiologicalImaging
2016English

Validation of 34betaE12 Immunoexpression in Clear Cell Papillary Renal Cell Carcinoma as a Sensitive Biomarker

Pathology
Forensic MedicinePathology
2017English

Clear Cell Papillary Renal Cell Carcinoma

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2019English

A Three-microRNA Signature as a Diagnostic and Prognostic Marker in Clear Cell Renal Cancer: An in Silico Analysis

PLoS ONE
Multidisciplinary
2017English

Clear Cell Papillary Renal Cell Carcinoma in a Patient With Urothelial Papillary Carcinoma of Renal Pyelon – Report of a Case

Lijecnicki Vjesnik
Medicine
2018English

Primary Renal Carcinoid With Bilateral Multiple Clear Cell Papillary Renal Cell Carcinomas

Case Reports in Pathology
2017English

Endogenous Retroviral Signatures Predict Immunotherapy Response in Clear Cell Renal Cell Carcinoma

Journal of Clinical Investigation
Medicine
2018English

Applicability of a Prognostic CT-based Radiomic Signature Model Trained on Stage I-Iii Non-Small Cell Lung Cancer in Stage IV Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

P2.16-06 Development and Validation of a Gene Expression-Based Nomogram to Predict Relapse in Stage I NSCLC: A Retrospective, Multi-Cohort Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy